

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
AUGUST 26, 2014**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

CV Therapeutics, Inc.

File No. 000-21643 -- CF# 31343

Gilead Sciences, Inc. (successor to CV Therapeutics, Inc.) submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information CV Therapeutics, Inc. excluded from the Exhibits to a Form 10-Q filed on November 3, 2000 and a Form 8-K filed on September 6, 2005.

Based on representations by Gilead Sciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

| Exhibit | Form | Filed | Confidential Treatment Granted |
|---------|------|-------------------|--------------------------------|
| 10.83 | 10-Q | November 3, 2000 | through July 21, 2018 |
| 10.1 | 8-K | September 6, 2005 | through July 21, 2018 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kevin M. O'Neill
Deputy Secretary